Melanocortin peptide PT-141 is a synthetic bremelanotide analog studied for sexual desire. Learn how it works, dosing, side effects, and legal status in the US.
PT-141, also known as bremelanotide, is a synthetic melanocortin peptide that activates melanocortin receptors in the brain and is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is given as a subcutaneous injection and is not approved for men or as a nasal spray in the United States. The peptide is often discussed alongside other melanocortin-based compounds, but PT-141 has a specific receptor profile and a narrow approved indication.
What Is Melanocortin Peptide PT-141?
Melanocortin peptides are a family of signaling molecules that includes alpha-melanocyte-stimulating hormone (alpha-MSH) and ACTH. PT-141 is a cyclic analog of alpha-MSH engineered to resist rapid breakdown in the body. The melanocortin-based peptide pt-141 binds most strongly to the MC4 receptor, which is involved in appetite, energy balance, and sexual motivation.
Researchers originally explored PT-141 for its effects on skin pigmentation. During early trials, participants reported unexpected increases in sexual desire, which shifted the focus toward sexual medicine. That history explains why PT-141 is sometimes grouped with tanning peptides, even though its only approved use is unrelated to pigmentation.
How PT-141 Works Compared With Other Options
PT-141 works through the central nervous system rather than through blood vessels. It activates MC4 receptors in the hypothalamus and related brain regions, which influence dopamine signaling and sexual motivation. This mechanism differs from PDE5 inhibitors like sildenafil, which increase blood flow to the penis.
Because the target is neurological, PT-141 may affect desire and arousal rather than erection mechanics alone. It is not a hormone and does not raise testosterone. Some researchers study whether combining pathways could help people who do not respond to standard treatments, but combination use is not FDA-approved.
Approved Use and Off-Label Interest
Vyleesi (bremelanotide) received FDA approval in 2019 for premenopausal women with acquired, generalized HSDD. The approved dose is 1.75 mg injected subcutaneously into the abdomen or thigh at least 45 minutes before anticipated sexual activity. It is not a daily medication.
Interest in pt-141 peptide for men comes from small early studies and widespread anecdotal reports. Those studies suggested possible benefits for erectile dysfunction, but the evidence is limited and the FDA has not approved PT-141 for male sexual dysfunction. Any use in men is off-label and should be supervised by a clinician.
An older pt-141 peptide nasal spray formulation was tested in clinical trials, but it was not the version that reached the market. Nasal sprays sold online as PT-141 are not FDA-approved and may contain unknown amounts of the drug. The approved product is an injectable only.
PT-141 and Related Melanocortin Peptides
Several melanocortin peptides target different receptors and treat very different conditions. The table below compares PT-141 with two other approved melanocortin-based drugs.
| Peptide | Primary receptor | FDA-approved use | Route |
|---|---|---|---|
| PT-141 (bremelanotide) | MC4R (also MC1R) | HSDD in premenopausal women | Subcutaneous injection |
| Afamelanotide (Scenesse) | MC1R | Erythropoietic protoporphyria | Subcutaneous implant |
| Setmelanotide (Imcivree) | MC4R | Certain genetic forms of obesity | Daily subcutaneous injection |
This table shows that melanocortin peptide is a broad category, not a single drug class. PT-141 is the only one approved for a sexual health indication, and each peptide carries its own risks and monitoring requirements.
Dosing, Side Effects, and Safety
A standard pt-141 peptide dosage chart from prescribing information lists 1.75 mg as the single approved dose. Patients should not use more than one dose in 24 hours or more than eight doses per month. A healthcare provider may check blood pressure before starting treatment because PT-141 can raise it temporarily.
Common side effects reported in trials include:
- Nausea (the most frequent complaint)
- Flushing and headache
- Injection site reactions
- Vomiting and fatigue
- Hyperpigmentation (darkening of the skin, gums, or nails) with frequent use
PT-141 is contraindicated in people with uncontrolled high blood pressure or known cardiovascular disease. It should not be combined with certain medications, including some antidepressants and blood pressure drugs, without medical guidance. Focal hyperpigmentation can be persistent and may not fade after stopping the drug.
Legal Status, Reviews, and Buying Online
PT-141 is a prescription drug in the United States. It is illegal to buy it without a prescription, and products labeled 'for research use only' are not intended for human consumption. Reading pt-141 peptide reviews can be misleading because online testimonials rarely verify the product's purity, dose, or origin.
Online listings for PT-141 often appear on unregulated vendor sites and marketplaces that prohibit prescription drugs. Those products may be underdosed, contaminated, or entirely different compounds. A prescription from a licensed provider and dispensing through a licensed pharmacy is the only legal and verifiable route in the US.
Anyone considering PT-141 should discuss cardiovascular history, current medications, and pregnancy status with a healthcare professional. PT-141 is not a cure for relationship issues or hormonal conditions, and it does not replace evaluation for underlying causes of sexual dysfunction.
The Bottom Line
PT-141 is a melanocortin peptide with one narrow FDA approval: HSDD in premenopausal women, delivered by subcutaneous injection. It is not approved for men, not available as a nasal spray, and not a substitute for medical evaluation. People who are curious about PT-141 should start with a clinician rather than an online vendor.
Frequently Asked Questions
Is PT-141 FDA-approved?
Yes. Bremelanotide, sold under the brand name Vyleesi, is FDA-approved for hypoactive sexual desire disorder in premenopausal women. It is not approved for men, for erectile dysfunction, or as a nasal spray.
What is the typical PT-141 dosage?
The approved dose is 1.75 mg injected subcutaneously at least 45 minutes before sexual activity. Patients should not exceed one dose in 24 hours or eight doses per month, and dosing should always be guided by a healthcare provider.
Does PT-141 come as a nasal spray?
Nasal formulations of PT-141 were studied in early clinical trials, but the FDA-approved product is an injectable. Nasal sprays marketed online as PT-141 are not FDA-approved and may not contain the labeled amount of the peptide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.